FIELD: biotechnology and medicine.
SUBSTANCE: metabiotic composition for normalizing the qualitative and quantitative composition of the intestinal microflora is proposed. The claimed composition includes metabolites of the probiotic strain B. subtilis with a molecular weight of 5–100 kDa and a filler, while the ratio of components, wt. %: metabolites of Bacillus subtilis is 0.6–5; filler is 95–99.4. A method of obtaining metabolites of Bacillus subtilis for their subsequent use in a metabolic composition is proposed. The method includes growing Bacillus subtilis in a liquid nutrient medium; centrifuging the culture suspension in a flow centrifuge to obtain a culture fluid; ultrafiltration of the resulting culture fluid with a cutoff of 100 kDa to obtain permeate; ultrafiltration of the resulting permeate with a cut-off threshold of 5 kDa. The use of the claimed composition for the treatment of post-COVID syndrome is proposed. The claimed composition has a broad antagonistic effect against pathogenic and opportunistic microorganisms, as well as an immunomodulatory effect.
EFFECT: intake of the claimed composition has a positive effect on the state of the gastrointestinal tract and on the psycho-emotional state of patients with post-COVID syndrome.
17 cl, 4 dwg, 4 tbl, 7 ex
